Buparlisib HCl | CAS# 1312445-63-8 | kinase inhibitor

MedKoo Cat#: 412131 | Name: Buparlisib HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Buparlisib hydrochloride is an investigational small molecule orally-available pan-class I phosphoinositide 3-kinase inhibitor.

Chemical Structure

Buparlisib HCl

CAS#1312445-63-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 412131

Name: Buparlisib HCl

CAS#: 1312445-63-8 (HCl)

Chemical Formula: C18H22ClF3N6O2

Exact Mass: 446.1445

Molecular Weight: 446.86

Elemental Analysis: C, 48.38; H, 4.96; Cl, 7.93; F, 12.75; N, 18.81; O, 7.16

Price and Availability

Size	Price	Availability
10mg	USD 350.00	2 Weeks
50mg	USD 600.00	2 Weeks
100mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1312445-63-8 (HCl) 944396-07-0 (free base)

Synonym

Buparlisib hydrochloride; BKM120AAA ; BKM120 AAA ; BKM120-AAA ; Buparlisib HCl

IUPAC/Chemical Name

2-Pyridinamine, 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)-, hydrochloride (1:1)

InChi Key

DGPLYAXBXJXEID-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H21F3N6O2.ClH/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27;/h9-11H,1-8H2,(H2,22,23);1H

SMILES Code

NC1=NC=C(C2=NC(N3CCOCC3)=NC(N4CCOCC4)=C2)C(C(F)(F)F)=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 446.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Narimatsu S, Mizukami T, Huang Y, Masubuchi Y, Suzuki T. In-vitro metabolic interaction of bunitrolol enantiomers in rabbit liver microsomes. J Pharm Pharmacol. 1996 Nov;48(11):1185-9. doi: 10.1111/j.2042-7158.1996.tb03918.x. PMID: 8961170. 2: Tsuchihashi H, Aono J, Nagatomo T, Kawada T, Ohta H, Imai S. Effects of bunitrolol on adrenergic and serotonergic receptors. Jpn J Pharmacol. 1987 Nov;45(3):349-56. doi: 10.1254/jjp.45.349. PMID: 2893855. 3: Tsuchihashi H, Nagotomo T, Imai S. Selectivity of bunitrolol for beta 1- and beta 2-adrenergic receptors and 5HT1B-receptors: assessment by biphasic Scatchard plots and biphasic displacement curve analysis with 125I-iodocyanopindolol and 3H-CGP12177. Jpn J Pharmacol. 1989 Jun;50(2):93-100. doi: 10.1254/jjp.50.93. PMID: 2570175. 4: Chiba K, Hayase N, Ichihara K. Effects of bunitrolol on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Apr;82(4):384-8. doi: 10.1002/jps.2600820410. PMID: 8096874. 5: Ono S, Tsutsui M, Gonzalez FJ, Satoh T, Masubuchi Y, Horie T, Suzuki T, Narimatsu S. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus. Pharmacogenetics. 1995 Apr;5(2):97-102. doi: 10.1097/00008571-199504000-00006. PMID: 7663534. 6: Ishida R, Fujita S, Suzuki T. Bunitrolol metabolism and its inhibition by cimetidine. J Pharm Pharmacol. 1988 Jan;40(1):64-5. doi: 10.1111/j.2042-7158.1988.tb05155.x. PMID: 2896780. 7: Matsuzaki J, Yamamoto C, Miyama T, Takanaga H, Matsuo H, Ishizuka H, Kawahara Y, Kuwano M, Naito M, Tsuruo T, Sawada Y. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier. Biopharm Drug Dispos. 1999 Mar;20(2):85-90. doi: 10.1002/(sici)1099-081x(199903)20:2<85::aid- bdd159>3.0.co;2-3. PMID: 10206323. 8: Narimatsu S, Masubuchi Y, Hosokawa S, Ohmori S, Kitada M, Suzuki T. Involvement of a cytochrome P4502D subfamily in human liver microsomal bunitrolol 4-hydroxylation. Biol Pharm Bull. 1994 Jun;17(6):803-7. doi: 10.1248/bpb.17.803. PMID: 7951142. 9: Haddad S, Poulin P, Funk C. Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquine. J Pharm Sci. 2010 Oct;99(10):4406-26. doi: 10.1002/jps.22136. PMID: 20310018. 10: Satoh K, Nunoki K, Goto T, Taira N. The mechanism underlying the vasodilator action of bunitrolol: contribution of alpha 1-adrenoceptor blocking action. J Cardiovasc Pharmacol. 1985 May-Jun;7(3):508-15. doi: 10.1097/00005344-198505000-00015. PMID: 2410682. 11: Narimatsu S, Kato R, Horie T, Ono S, Tsutsui M, Yabusaki Y, Ohmori S, Kitada M, Ichioka T, Shimada N, Kato R, Ishikawa T. Enantioselectivity of bunitrolol 4-hydroxylation is reversed by the change of an amino acid residue from valine to methionine at position 374 of cytochrome P450-2D6. Chirality. 1999;11(1):1-9. doi: 10.1002/(SICI)1520-636X(1999)11:1<1::AID-CHIR1>3.0.CO;2-E. PMID: 9914647. 12: Keul J, Lehmann M, Wybitul K. Zur Wirkung von Bunitrolol auf Herzfrequenz, metabolische Grössen bei Körperarbeit und Leistungsverhalten [Effect of bunitrolol on heart rate, metabolic parameters during physical exercise, and performance]. Arzneimittelforschung. 1981;31(11):1948-53. German. PMID: 6119096. 13: Takeda N, Nakamura I, Hatanaka T, Ohkubo T, Nagano M. Effects of bunitrolol on myocardial contractility and left ventricular myosin isoenzyme pattern. Arzneimittelforschung. 1988 Sep;38(9):1280-2. PMID: 2906244. 14: Pozenel H. Vergleichende ergometrische Untersuchungen nach Anwendung von Practolol und Bunitrolol [Comparable ergometric examinations before and after administration of practolol and bunitrolol (author's transl)]. Wien Klin Wochenschr. 1975 Jan 10;87(1):19-25. German. PMID: 236621. 15: Okabayashi T, Naito S, Arakawa K. Antihypertensive effect of intravenously and orally administered bunitrolol (Kö 1366). Arzneimittelforschung. 1979;29(9):1417-21. PMID: 42418. 16: Jonker JJ, de Klerk J, den Ottolander GJ. A double blind cross-over comparison of bunitrolol and placebo in the treatment of angina pectoris. Arzneimittelforschung. 1981;31(7):1140-2. PMID: 6115654. 17: Beumer HM, Ritter W. Antagonism of fenoterol against beta-blocking drugs bunitrolol and practolol in asthmatics. Respiration. 1975;32(5):363-7. doi: 10.1159/000193666. PMID: 241102. 18: Lund-Johansen P. Central haemodynamic effects of beta blockers in hypertension. A comparison between atenolol, metoprolol, timolol, penbutolol, alprenolol pindolol and bunitrolol. Eur Heart J. 1983 Jul;4 Suppl D:1-12. doi: 10.1093/eurheartj/4.suppl_d.1. PMID: 6137366. 19: Nagakura A, Kohei H. Simultaneous determination of bunitrolol and its metabolite in biological fluids, plasma and urine. J Chromatogr. 1982 Oct 8;232(1):137-43. doi: 10.1016/s0378-4347(00)86016-8. PMID: 6128351. 20: Banim SO, da Silva A, Balcon R. Haemodynamic observations with KO. 1366 (bunitrolol), a new beta-adrenergic blocking agent. Curr Med Res Opin. 1977;4(9):630-4. doi: 10.1185/03007997709115282. PMID: 22426.